EUVIMEDEUVIMED entdecken
Crossref

Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego

Krzysztof Jamroziak

Hematologia · 2015

DOI: 10.5603/hem.2015.0011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematologia, 2015. Verfasst von Krzysztof Jamroziak.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During nearly two decades there has been continuous progress in the therapy of plasma cell myeloma resulting in significant prolongation of patients’ overall survival. Since 2010 the efficacy and toxicity of chemotherapy regimens including immunomodulatory drugs and proteasome inhibitors have been further optimized based on the results of numerous, large phase 3 randomized clinical trials. Moreover, intensive efforts have been made to identify novel molecular drug targets to individualize treatment and overcome resistance to existing therapies. Currently, the most promising therapeutic strategy is immunotherapy, especially development of monoclonal antibodies against CD38 antigen .

Zitieren

APA

Jamroziak, K. (2015). Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego. Hematologia. https://doi.org/10.5603/hem.2015.0011

Vancouver

Jamroziak K. Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego. Hematologia. 2015. doi:10.5603/hem.2015.0011

BibTeX
@article{Jamroziak2015,
  author = {Jamroziak, Krzysztof},
  title = {Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego},
  journal = {Hematologia},
  year = {2015},
  doi = {10.5603/hem.2015.0011}
}
Kostenlos starten →